PATENT CLAIM ANALYSIS

Application Number: 15964771
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "249000"]

Abstract:
The present invention relates to a subtype selective partial agonist of α6 containing nicotinic acetylcholine receptors. Due to its uniquely selective and functional profile, 9-methyl-3-pyridin-3-yl-3,9-diaza-bicyclo[3.3.1]nonane may be useful in the treatment, prevention and/or alleviation of a disease, disorder and/or condition which is responsive to activation of a nicotinic acetylcholine receptor (nAChR) in a subject, wherein the nAChR comprises at least one cholinergic receptor nicotinic alpha 6 subunit (nAChRa6). Preferably, said disease, disorder and/or condition is a Parkinsonian disorder or pain.

Claim (Index 1):
A method for treating, preventing, and/or alleviating a disease, disorder and/or condition that is a systemic atrophy primarily affecting the central nervous system, a Parkinsonian disorder, or pain in a subject comprising administering a therapeutically effective amount of 9-methyl-3-pyridin-3-yl-3,9-diaza-bicyclo[3.3.1]nonane, or a pharmaceutically acceptable salt thereof, to said subject.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 91.0
- Lexical Diversity: 1.49231
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12087004', '12160567', '12161905', '12093655', '12593779']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7921511337812471
- 35 USC 102 Novelty (BERT): 0.54874057774841
- Combined Prediction Score: 0.7678100781779634
- Mean Citation Score: 365.378578
- Max Citation Score: 421.349
- Similarity Product: 319.5305477396845

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test